Rochester, NY, September 28, 2022 – iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services, today announced it has signed a definitive agreement to be acquired by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life science and healthcare sectors. Ampersand’s investment will support the expansion of iuvo’s integrated service portfolio and laboratory capacity, and fund an active inorganic growth strategy. As part of the transaction, iuvo also announced the appointment of Daniel Spasic as Chairman of the company’s Board of Directors. Daniel is a pharmaceutical services executive with over 25 years of experience in the CRO industry.
Read the full press release here.
